Peanut Allergy Treatment Works Long Term

Four years after taking a probiotic and peanut protein for 18 months, two-thirds of children in a small clinical trial can eat peanuts with no health issues.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, AIRPIXIn 2013, researchers at Murdoch Children’s Research Institute in Australia dosed 48 children either with a probiotic with increasing amounts of a peanut protein, a treatment known as PPOIT, or with a placebo once daily for a year and a half. This week (August 15), they reported that some 70 percent of the participants who received PPOIT can ingest peanut-containing foods with no adverse reactions, according to a study published in The Lancet Child & Adolescent Health.

That result represents only a slight dip from the original results that found 82 percent of the treated children could tolerate peanuts one month after finishing their PPOIT courses, suggesting the treatment is the first long-lasting option for those who suffer from a peanut allergy.

“These children had been eating peanut freely in their diet without having to follow any particular program of peanut intake in the years after treatment was completed,” lead researcher Mimi Tang says in a statement sent to The Scientist. “This is a major step forward in identifying an effective treatment to address the food allergy problem in Western societies.”

The probiotic used was Lactobacillus rhamnosus, a bacterium that may help mitigate allergic symptoms. “The probiotic acts on the immune system, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies